Shares of drugmaker Cytokinetics CYTK.O rise 1.7% to $79.27 premarket.
CYTK says detailed late-stage data showed its drug, aficamten, significantly improved symptoms and exercise capacity in patients with a genetic heart condition that currently has no approved treatments.
The drug is already approved as Myqorzo for oHCM — the obstructive form of the condition called hypertrophic cardiomyopathy in which thickened heart muscles block blood flow.
Myqorzo competes with Bristol Myers Squibb's BMY.N Camzyos in the oHCM segment.
The company is seeking to expand its use to the non-obstructive form (nHCM), which causes heart muscle thickening without blocking blood flow.
CYTK•
